Research ArticleOriginal Article

Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants

Ludi Yang, Peiwei Chai, Jie Yu and Xianqun Fan
Cancer Biology & Medicine February 2021, 18 (1) 298-307; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0559

References

  1. 1.↵
    2. Contini C,
    3. Di Nuzzo M,
    4. Barp N,
    5. Bonazza A,
    6. De Giorgio R,
    7. Tognon M, et al.
    The novel zoonotic COVID-19 pandemic: an expected global health concern. J Infect Dev Ctries. 2020; 14: 254–64.
    OpenUrlCrossRef
  2. 2.
    2. Singhal T.
    A review of coronavirus disease-2019 (COVID-19). Indian J Pediatr. 2020; 87: 281–6.
    OpenUrlCrossRefPubMed
  3. 3.
    2. Chan KW,
    3. Wong VT,
    4. Tang SCW.
    COVID-19: an update on the epidemiological, clinical, preventive and therapeutic evidence and guidelines of integrative Chinese-Western medicine for the management of 2019 Novel Coronavirus Disease. Am J Chin Med. 2020; 48: 737–62.
    OpenUrlPubMed
  4. 4.
    2. Ge H,
    3. Wang X,
    4. Yuan X,
    5. Xiao G,
    6. Wang C,
    7. Deng T, et al.
    The epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect Dis. 2020; 39: 1011–9.
    OpenUrlCrossRefPubMed
  5. 5.
    2. Harapan H,
    3. Itoh N,
    4. Yufika A,
    5. Winardi W,
    6. Keam S,
    7. Te H, et al.
    Coronavirus disease 2019 (COVID-19): a literature review. J Infect Public Health. 2020; 13: 667–73.
    OpenUrlCrossRefPubMed
  6. 6.
    2. Palacios Cruz M,
    3. Santos E,
    4. Velazquez Cervantes MA,
    5. Leon Juarez M.
    COVID-19, a worldwide public health emergency. Rev Clin Esp. 2020; S0014-2565(20)30092-8.
  7. 7.
    2. Velavan TP,
    3. Meyer CG.
    The COVID-19 epidemic. Trop Med Int Health. 2020; 25: 278–80.
    OpenUrlPubMed
  8. 8.↵
    2. Cao Y,
    3. Cai K,
    4. Xiong L.
    Coronavirus disease 2019: a new severe acute respiratory syndrome from Wuhan in China. Acta Virol. 2020; 64: 245–50.
    OpenUrl
  9. 9.↵
    2. Organization WH.
    Coronavirus disease (COVID-2019) situation reports. 2020.
  10. 10.↵
    2. Tian S,
    3. Hu N,
    4. Lou J,
    5. Chen K,
    6. Kang X,
    7. Xiang Z, et al.
    Characteristics of COVID-19 infection in Beijing. J Infect. 2020; 80: 401–6.
    OpenUrlCrossRefPubMed
  11. 11.
    2. Pascarella G,
    3. Strumia A,
    4. Piliego C,
    5. Bruno F,
    6. Del Buono R,
    7. Costa F, et al.
    COVID-19 diagnosis and management: a comprehensive review. J Intern Med. 2020; 288: 192–206.
    OpenUrlCrossRefPubMed
  12. 12.
    2. Li LQ,
    3. Huang T,
    4. Wang YQ,
    5. Wang ZP,
    6. Liang Y,
    7. Huang TB, et al.
    COVID-19 patients’ clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. 2020; 92: 577–83.
    OpenUrlCrossRefPubMed
  13. 13.
    2. Jin Y,
    3. Yang H,
    4. Ji W,
    5. Wu W,
    6. Chen S,
    7. Zhang W, et al.
    Virology, epidemiology, pathogenesis, and control of COVID-19. Viruses 2020; 12: 372.
    OpenUrlCrossRefPubMed
  14. 14.
    2. Lake MA.
    What we know so far: COVID-19 current clinical knowledge and research. Clin Med (Lond). 2020; 20: 124–7.
    OpenUrl
  15. 15.↵
    2. Yu J,
    3. Chai P,
    4. Ge S,
    5. Fan X.
    Recent understandings toward coronavirus disease 2019 (COVID-19): from bench to bedside. Front Cell Dev Biol. 2020; 8: 476.
    OpenUrl
  16. 16.↵
    2. Esakandari H,
    3. Nabi-Afjadi M,
    4. Fakkari-Afjadi J,
    5. Farahmandian N,
    6. Miresmaeili SM,
    7. Bahreini E.
    A comprehensive review of covid-19 characteristics. Biol Proceed Online. 2020; 22: 19.
    OpenUrl
  17. 17.↵
    2. Dhama K,
    3. Khan S,
    4. Tiwari R,
    5. Sircar S,
    6. Bhat S,
    7. Malik YS, et al.
    Coronavirus disease 2019-COVID-19. Clin Microbiol Rev. 2020; 33: e00028–20.
    OpenUrlCrossRefPubMed
  18. 18.
    2. Guan W,
    3. Ni Z,
    4. Hu Y,
    5. Liang W,
    6. Ou C,
    7. He J, et al.
    Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020; 382: 1708–20.
    OpenUrlCrossRefPubMed
  19. 19.
    2. Chan JF,
    3. Yuan S,
    4. Kok KH,
    5. To KK,
    6. Chu H,
    7. Yang J, et al.
    A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395: 514–23.
    OpenUrlCrossRefPubMed
  20. 20.
    2. Bajema KL,
    3. Oster AM,
    4. McGovern OL,
    5. Lindstrom S,
    6. Stenger MR,
    7. Anderson TC, et al.
    Persons evaluated for 2019 novel coronavirus – United States, January 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 166–70.
    OpenUrlCrossRefPubMed
  21. 21.
    2. Huang C,
    3. Wang Y,
    4. Li X,
    5. Ren L,
    6. Zhao J,
    7. Hu Y, et al.
    Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395: 497–506.
    OpenUrlCrossRefPubMed
  22. 22.
    2. Chen N,
    3. Zhou M,
    4. Dong X,
    5. Qu J,
    6. Gong F,
    7. Han Y, et al.
    Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020; 395: 507–13.
    OpenUrlCrossRefPubMed
  23. 23.
    2. Meo SA,
    3. Alhowikan AM,
    4. Al-Khlaiwi T,
    5. Meo IM,
    6. Halepoto DM,
    7. Iqbal M, et al.
    Novel coronavirus 2019-nCOV: prevalence, biological and clinical characteristics comparison with SARS-CoV and MERS-CoV. Eur Rev Med Pharmacol Sci. 2020; 24: 2012–9.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Singh A,
    3. Shaikh A,
    4. Singh R,
    5. Singh AK.
    COVID-19: from bench to bed side. Diabetes Metab Syndr. 2020; 14: 277–81.
    OpenUrlCrossRef
  25. 25.↵
    2. Espinosa OA,
    3. Zanetti ADS,
    4. Antunes EF,
    5. Longhi FG,
    6. Matos TA,
    7. Battaglini PF.
    Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis. Rev Inst Med Trop Sao Paulo. 2020; 62: e43.
  26. 26.
    2. Chow N,
    3. Fleming-Dutra K,
    4. Gierke R,
    5. Hall A,
    6. Hughes M,
    7. Pilishvili T, et al.
    Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019 – United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 382–6.
    OpenUrlCrossRefPubMed
  27. 27.
    2. Liang WH,
    3. Guan WJ,
    4. Li CC,
    5. Li YM,
    6. Liang HR,
    7. Zhao Y, et al.
    Clinical characteristics and outcomes of hospitalised patients with COVID-19 treated in Hubei (epicentre) and outside Hubei (non-epicentre): a nationwide analysis of China. Eur Respir J. 2020; 55: 2000562.
    OpenUrlPubMed
  28. 28.
    2. Wu Z,
    3. McGoogan JM.
    Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA 2020; 323: 1239–42.
    OpenUrlCrossRefPubMed
  29. 29.
    2. Zhou F,
    3. Yu T,
    4. Du R,
    5. Fan G,
    6. Liu Y,
    7. Liu Z, et al.
    Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395: 1054–62.
    OpenUrlCrossRefPubMed
  30. 30.
    2. de Lucena TMC,
    3. da Silva Santos AF,
    4. de Lima BR,
    5. de Albuquerque Borborema ME,
    6. de Azevedo Silva J.
    Mechanism of inflammatory response in associated comorbidities in COVID-19. Diabetes Metab Syndr. 2020; 14: 597–600.
    OpenUrlPubMed
  31. 31.
    2. Dayal D.
    We urgently need guidelines for managing COVID-19 in children with comorbidities. Acta Paediatr. 2020; 109: 1497–8.
    OpenUrl
  32. 32.
    2. Ejaz H,
    3. Alsrhani A,
    4. Zafar A,
    5. Javed H,
    6. Junaid K,
    7. Abdalla AE, et al.
    Covid-19 and comorbidities: deleterious impact on infected patients. J Infect Public Health. 2020; 13: 1833–9.
    OpenUrl
  33. 33.
    2. Bajgain KT,
    3. Badal S,
    4. Bajgain BB,
    5. Santana MJ.
    Prevalence of comorbidities among individuals with COVID-19: a rapid review of current literature. Am J Infect Control. 2020; S0196-6553(20)30637-4.
  34. 34.
    2. Aghagoli G,
    3. Gallo Marin B,
    4. Soliman LB,
    5. Sellke FW.
    Cardiac involvement in COVID-19 patients: risk factors, predictors, and complications: a review. J Card Surg. 2020; 35: 1302–5.
    OpenUrlCrossRefPubMed
  35. 35.↵
    2. Cheng Y,
    3. Luo R,
    4. Wang K,
    5. Zhang M,
    6. Wang Z,
    7. Dong L, et al.
    Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int. 2020; 97: 829–38.
    OpenUrlCrossRefPubMed
  36. 36.↵
    2. Fidler MM,
    3. Bray F,
    4. Soerjomataram I.
    The global cancer burden and human development: a review. Scand J Public Health. 2018; 46: 27–36.
    OpenUrlPubMed
  37. 37.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2020. CA Cancer J Clin. 2020; 70: 7–30.
    OpenUrlCrossRefPubMed
  38. 38.↵
    2. Addeo A,
    3. Friedlaender A.
    Cancer and COVID-19: unmasking their ties. Cancer Treat Rev. 2020; 88: 102041.
    OpenUrl
  39. 39.
    2. Gao Y,
    3. Liu M,
    4. Shi S,
    5. Chen Y,
    6. Sun Y,
    7. Chen J, et al.
    Cancer is associated with the severity and mortality of patients with COVID-19: a systematic review and meta-analysis. MedRxiv 2020; DOI: 10.1101/2020.05.01.20087031
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    2. Giannakoulis VG,
    3. Papoutsi E,
    4. Siempos II.
    Effect of cancer on clinical outcomes of patients with COVID-19: a meta-analysis of patient data. JCO Global Oncol. 2020; 6: 799–808.
    OpenUrl
  41. 41.↵
    2. Dai M,
    3. Liu D,
    4. Liu M,
    5. Zhou F,
    6. Li G,
    7. Chen Z, et al.
    Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak. Cancer Discov. 2020; 10: 783–91.
    OpenUrlAbstract/FREE Full Text
  42. 42.
    2. Ma J,
    3. Yin J,
    4. Qian Y,
    5. Wu Y.
    Clinical characteristics and prognosis in cancer patients with COVID-19: a single center’s retrospective study. J Infect. 2020; 81: 318–56.
    OpenUrlCrossRefPubMed
  43. 43.↵
    2. Desai A,
    3. Sachdeva S,
    4. Parekh T,
    5. Desai R.
    COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 2020; 6: 557–9.
    OpenUrlPubMed
  44. 44.
    2. Cook G,
    3. John Ashcroft A,
    4. Pratt G,
    5. Popat R,
    6. Ramasamy K,
    7. Kaiser M, et al.
    Real-world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID-19 disease) in patients with multiple myeloma receiving systemic anti-cancer therapy. Br J Haematol. 2020; 190: e83–6.
    OpenUrlPubMed
  45. 45.
    2. Sharpless NE.
    COVID-19 and cancer. Science. 2020; 368: 1290.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    2. Extance A.
    COVID-19 and long term conditions: what if you have cancer, diabetes, or chronic kidney disease? BMJ. 2020; 368: m1174.
    OpenUrlFREE Full Text
  47. 47.↵
    2. Liang W,
    3. Guan W,
    4. Chen R,
    5. Wang W,
    6. Li J,
    7. Xu K, et al.
    Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020; 21: 335–7.
    OpenUrlCrossRefPubMed
  48. 48.↵
    2. Stang A.
    Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010; 25: 603–5.
    OpenUrlCrossRefPubMedWeb of Science
  49. 49.↵
    2. Wells G,
    3. Shea B,
    4. O’Connell D,
    5. Robertson J,
    6. Peterson J,
    7. Welch V, et al.
    The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analyses. 2011.
  50. 50.↵
    2. Higgins JPT,
    3. Thomas J,
    4. Chandler J,
    5. Cumpston M,
    6. Li T,
    7. Page MJ, et al
    (editors). Cochrane handbook for systematic reviews of interventions version 6.0 (updated July 2019). Cochrane 2019. 2019.
  51. 51.
    Epidemiology Working Group for NCIP Epidemic Response CCDC, Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41: 145–51.
    OpenUrlCrossRefPubMed
  52. 52.↵
    2. Miyashita H,
    3. Mikami T,
    4. Chopra N,
    5. Yamada T,
    6. Chernyavsky S,
    7. Rizk D, et al.
    Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York city. Ann Oncol. 2020; 31: 1088–9.
    OpenUrlPubMed
  53. 53.
    2. Goyal P,
    3. Choi JJ,
    4. Pinheiro LC,
    5. Schenck EJ,
    6. Chen R,
    7. Jabri A, et al.
    Clinical characteristics of COVID-19 in New York city. N Engl J Med. 2020; 382: 2372–4.
    OpenUrlPubMed
  54. 54.
    2. Baker KF,
    3. Hanrath AT,
    4. Schim van der Loeff I,
    5. Tee SA,
    6. Capstick R,
    7. Marchitelli G, et al.
    COVID-19 management in a UK NHS Foundation Trust with a high consequence infectious diseases centre: a detailed descriptive analysis. medRxiv 2020; 2020.05.14.20100834.
  55. 55.
    2. Benelli G,
    3. Buscarini E,
    4. Canetta C,
    5. La Piana G,
    6. Merli G,
    7. Scartabellati A, et al.
    SARS-CoV-2 comorbidity network and outcome in hospitalized patients in Crema, Italy. medRxiv 2020; 2020.04.14.20053090.
  56. 56.
    2. Giorgi Rossi P,
    3. Marino M,
    4. Formisano D,
    5. Venturelli F,
    6. Vicentini M,
    7. Grilli R.
    Characteristics and outcomes of a cohort of SARS-CoV-2 patients in the province of Reggio Emilia, Italy. medRxiv 2020; 2020.04.13.20063545.
  57. 57.
    2. Nikpouraghdam M,
    3. Jalali Farahani A,
    4. Alishiri G,
    5. Heydari S,
    6. Ebrahimnia M,
    7. Samadinia H, et al.
    Epidemiological characteristics of coronavirus disease 2019 (COVID-19) patients in Iran: a single center study. J Clin Virol. 2020; 127: 104378.
    OpenUrlCrossRefPubMed
  58. 58.
    2. Borobia AM,
    3. Carcas AJ,
    4. Arnalich F,
    5. Alvarez-Sala R,
    6. Montserrat J,
    7. Quintana M, et al.
    A cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv 2020; 2020.04.29.20080853.
  59. 59.
    2. Ricoca Peixoto V,
    3. Vieira A,
    4. Aguiar P,
    5. Sousa P,
    6. Carvalho C,
    7. Thomas DR, et al.
    COVID-19: Determinants of hospitalization, ICU and death among 20,293 reported cases in Portugal. medRxiv 2020; 2020.05.29.20115824.
  60. 60.
    2. Duanmu YY,
    3. Brown IP,
    4. Gibb WR,
    5. Singh J,
    6. Matheson LW,
    7. Blomkalns AL, et al.
    Characteristics of emergency department patients with COVID-19 at a single site in Northern California: clinical observations and public health implications. Acad Emerg Med. 2020; 27: 505–9.
    OpenUrl
  61. 61.
    2. Gold JAW,
    3. Wong KK,
    4. Szablewski CM,
    5. Patel PR,
    6. Rossow J,
    7. da Silva J, et al.
    Characteristics and clinical outcomes of adult patients hospitalized with COVID-19 – Georgia, March 2020. MMWR Morb Mortal Wkly Rep. 2020; 69: 545–50.
    OpenUrlCrossRefPubMed
  62. 62.
    2. Sami R,
    3. Soltaninejad F,
    4. Amra B,
    5. Naderi Z,
    6. Haghjooy Javanmard S,
    7. Iraj B, et al.
    A one-year hospital-based prospective COVID-19 open-cohort in the Eastern Mediterranean region: the Khorshid COVID Cohort (KCC) study. medRxiv 2020; 2020.05.11.20096727.
  63. 63.
    2. Regina J,
    3. Papadimitriou-Olivgeris M,
    4. Burger R,
    5. Filippidis P,
    6. Tschopp J,
    7. Desgranges F, et al.
    Epidemiology, risk factors and clinical course of SARS-CoV-2 infected patients in a Swiss University Hospital: an observational retrospective study. medRxiv 2020; 2020.05.11.20097741.
  64. 64.
    2. Ji W,
    3. Huh K,
    4. Kang M,
    5. Hong J,
    6. Bae GH,
    7. Lee R, et al.
    Effect of underlying comorbidities on the infection and severity of COVID-19 in South Korea. medRxiv 2020; 2020.05.08.20095174.
  65. 65.
    2. Joharatnam-Hogan N,
    3. Hochhauser D,
    4. Shiu K-K,
    5. Rush H,
    6. Crolley V,
    7. Butcher E, et al.
    Outcomes of the 2019 novel coronavirus in patients with or without a history of cancer – a multi-centre North London experience. medRxiv 2020; 2020.04.16.20061127.
  66. 66.
    2. Stroppa EM,
    3. Toscani I,
    4. Citterio C,
    5. Anselmi E,
    6. Zaffignani E,
    7. Codeluppi M, et al.
    Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy). Future Oncol. 2020; 16: 1425–32.
    OpenUrl
  67. 67.
    2. Mehta V,
    3. Goel S,
    4. Kabarriti R,
    5. Cole D,
    6. Goldfinger M,
    7. Acuna-Villaorduna A, et al.
    Case fatality rate of cancer patients with COVID-19 in a New York Hospital System. Cancer Discov. 2020; 10: 935–41.
    OpenUrlAbstract/FREE Full Text
  68. 68.
    2. Yang F,
    3. Shi S,
    4. Zhu J,
    5. Shi J,
    6. Dai K,
    7. Chen X.
    Clinical characteristics and outcomes of cancer patients with COVID-19. J Med Virol. 2020; 92: 2067–73.
    OpenUrlPubMed
  69. 69.↵
    2. Bray F,
    3. Ferlay J,
    4. Soerjomataram I,
    5. Siegel RL,
    6. Torre LA,
    7. Jemal A.
    Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018; 68: 394–424.
    OpenUrlCrossRefPubMed
  70. 70.↵
    2. Chai P,
    3. Yu J,
    4. Ge S,
    5. Jia R,
    6. Fan X.
    Genetic alteration, RNA expression, and DNA methylation profiling of coronavirus disease 2019 (COVID-19) receptor ACE2 in malignancies: a pan-cancer analysis. J Hematol Oncol. 2020; 13: 43.
    OpenUrlCrossRefPubMed
  71. 71.
    2. Katopodis P,
    3. Anikin V,
    4. Randeva HS,
    5. Spandidos DA,
    6. Chatha K,
    7. Kyrou I, et al.
    Pancancer analysis of transmembrane protease serine 2 and cathepsin L that mediate cellular SARSCoV2 infection leading to COVID-19. Int J Oncol. 2020; 57: 533–9.
    OpenUrl
  72. 72.
    2. Hou Y,
    3. Zhao J,
    4. Martin W,
    5. Kallianpur A,
    6. Chung MK,
    7. Jehi L, et al.
    New insights into genetic susceptibility of COVID-19: an ACE2 and TMPRSS2 polymorphism analysis. BMC Med. 2020; 18: 216.
    OpenUrlCrossRefPubMed
  73. 73.
    2. Yang J,
    3. Li H,
    4. Hu S,
    5. Zhou Y.
    ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19. Aging (Albany NY). 2020; 12: 6518–35.
    OpenUrl
  74. 74.↵
    2. Bao R,
    3. Hernandez K,
    4. Huang L,
    5. Luke JJ.
    ACE2 and TMPRSS2 expression by clinical, HLA, immune, and microbial correlates across 34 human cancers and matched normal tissues: implications for SARS-CoV-2 COVID-19. J Immunother Cancer. 2020; 8: e001020.
  75. 75.↵
    2. Liu C,
    3. Zhao Y,
    4. Okwan-Duodu D,
    5. Basho R,
    6. Cui X.
    COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020; 17: 519–27.
    OpenUrl
  76. 76.↵
    2. Serraino D.
    COVID-19 and cancer: looking for evidence. Eur J Surg Oncol. 2020; 46: 929–30.
    OpenUrl
  77. 77.↵
    2. Spezzani V,
    3. Piunno A,
    4. Iselin HU.
    Benign COVID-19 in an immunocompromised cancer patient – the case of a married couple. Swiss Med Wkly. 2020; 150: w20246.
    OpenUrl
  78. 78.↵
    2. Barlesi F,
    3. Foulon S,
    4. Bayle A,
    5. Gachot B,
    6. Pommeret F,
    7. Willekens C, et al.
    Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments. AACR Annual Meeting 2020 Online. April 28, 2020; abstr.CT403.
  79. 79.↵
    2. Vuagnat P,
    3. Frelaut M,
    4. Ramtohul T,
    5. Basse C,
    6. Diakite S,
    7. Noret A, et al.
    COVID-19 in breast cancer patients: a cohort at the Institut Curie Hospitals in the Paris area. Breast Cancer Res. 2020; 22: 55.
    OpenUrl
  80. 80.↵
    2. Gebhard C,
    3. Regitz-Zagrosek V,
    4. Neuhauser HK,
    5. Morgan R,
    6. Klein SL.
    Impact of sex and gender on COVID-19 outcomes in Europe. Biol Sex Differ. 2020; 11: 29.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords